View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 6, 2022

Moderna doses first subject in Phase I EBV vaccine trial

The trial will analyse the safety and tolerability of the shot in healthy adult participants aged 18 to 30 years. 

By Vishnu Priyan

Moderna has dosed the first subject in the Phase I Eclipse clinical trial of its Epstein-Barr Virus (EBV) vaccine candidate, mRNA-1189.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The EBV vaccine comprises four messenger ribonucleic acids (mRNAs) that encode EBV envelope glycoproteins, namely gH; gL; gp42 and gp220.

These glycoproteins are required for the entry of the virus into B-cells, as well as epithelial surface cells.

The observer-blind, randomised, placebo-controlled trial will evaluate the safety and tolerability of the vaccine in healthy adult subjects aged 18 to 30 years.

The trial will enrol around 270 subjects and be carried out at nearly 15 centres in the US.

Moderna CEO Stéphane Bancel said: “EBV is one of the most common viral infections in the world, and despite the fact that it causes infectious mononucleosis, which impacts millions of adolescents globally, no vaccine is currently available.

“The start of this Phase I study is a significant milestone as we continue to advance mRNA vaccines against latent viruses, which remain in the body for life after infection and can lead to chronic medical conditions.”

A prevalent viral infection, EBV is contracted in early stages of childhood or adolescence through bodily fluids such as saliva.

Primary EBV infection in adolescence can cause infectious mononucleosis (IM), a clinical syndrome that includes fever, sore throat, fatigue and lymphadenopathy.

Candidates against respiratory, latent and tropical viruses are part of the mRNA vaccine portfolio of Moderna.

The company focuses on the development of shots against latent viruses, including EBV, cytomegalovirus (CMV) and human immunodeficiency virus (HIV), which currently have no approved vaccines.

Last August, Moderna dosed the first participant in the Phase I trial of mRNA-6231 to treat autoimmune diseases.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena